SCHEMBL24637209

SCHEMBL24637209

C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCN(C(C)(C)C)CC1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 0.81
ERBB2 P04626 8/20 0.81
ERBB3 P21860 3/20 0.81
ERBB4 Q15303 3/20 0.81
KIT P10721 2/20 0.81
SRC P12931 2/20 0.81
KDR P35968 2/20 0.81
BMPR1B O00238 1/20 0.81
CIT O14578 1/20 0.81
MAP2K7 O14733 1/20 0.81
GAK O14976 1/20 0.81
EPHB6 O15197 1/20 0.81
MAP3K7 O43318 1/20 0.81
RIPK2 O43353 1/20 0.81
STK17B O94768 1/20 0.81
STK10 O94804 1/20 0.81
ABL1 P00519 1/20 0.81
LCK P06239 1/20 0.81
FYN P06241 1/20 0.81
YES1 P07947 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24637153 0.94 EGFR (0.73) EGFRERBB2ERBB3ERBB4KIT
SCHEMBL3585133 0.91 EGFR (0.88) EGFRERBB2ERBB3ERBB4KIT
SCHEMBL13882947 0.91 EGFR (0.86) EGFRERBB2ERBB3ERBB4KIT
SCHEMBL3581795 0.90 EGFR (0.81) EGFRERBB2ERBB3ERBB4KIT
Canertinib SCHEMBL29655741 0.89 EGFR (1.00) EGFRERBB2ERBB3ERBB4KIT
Canertinib SCHEMBL29623482 0.89 EGFR (1.00) EGFRERBB2ERBB3ERBB4KIT
Canertinib SCHEMBL29368458 0.89 EGFR (1.00) EGFRERBB2ERBB3ERBB4KIT
SCHEMBL22962549 0.89 EGFR (0.84) EGFRERBB2ERBB3ERBB4KIT
Canertinib SCHEMBL54837 0.89 EGFR (1.00) EGFRERBB2ERBB3ERBB4KIT
SCHEMBL24637211 0.89 EGFR (0.77) EGFRERBB2ERBB3ERBB4KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220313829-A1 EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2022-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220313829-A1 EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF EGFR, ERBB2, ERBB3 EGFR 1/4885ERBB2 2/4885ERBB3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.